POD-6.02: A Multicenter, Randomized, Phase III Trial of a Novel, Autologous, Therapeutic Vaccine (Vitespen) vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma